Evidence map›Paper›PMID 35158853›Full record

ArticleCancers2022

Expression of 3-Methylcrotonyl-CoA Carboxylase in Brain Tumors and Capability to Catabolize Leucine by Human Neural Cancer Cells.

Eduard Gondáš, Alžbeta Kráľová Trančíková, Eva Baranovičová, Jakub Šofranko, Jozef Hatok, Bhavani S Kowtharapu, Tomáš Galanda, Dušan Dobrota, Peter Kubatka, Dietrich Busselberg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Substrate-enhanced filamentation of 3-methylcrotonyl-CoA carboxylase inbioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Eduard GondášDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4D, 036 01 Martin, Slovakia.
Alžbeta Kráľová TrančíkováBiomedical Center Martin-BioMed, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia.ORCID 0000-0002-4743-4952
Eva BaranovičováBiomedical Center Martin-BioMed, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia.
Jakub ŠofrankoDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4D, 036 01 Martin, Slovakia.
Jozef HatokDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4D, 036 01 Martin, Slovakia.
Bhavani S KowtharapuProf. Brien Holden Eye Research Center, L V Prasad Eye Institute, Champalimaud Translational Centre for Eye Research Kallam Anji Reddy Campus, Hyderabad 500034, India.ORCID 0000-0002-2336-5729
Tomáš GalandaDepartment of Neurosurgery, Slovak Medical University, Roosevelt Hospital, 975 17 Banska Bystrica, Slovakia.
Dušan DobrotaDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4D, 036 01 Martin, Slovakia.
Peter KubatkaDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4D, 036 01 Martin, Slovakia.ORCID 0000-0003-4312-5076
Dietrich BusselbergDepartment of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Education City, Qatar Foundation, Doha 24144, Qatar.ORCID 0000-0001-5196-3366
Radovan MurínDepartment of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Malá Hora 4D, 036 01 Martin, Slovakia.ORCID 0000-0002-2952-0398
Comenius University Bratislava · SKL V Prasad Eye Institute · INSlovak Academy of Sciences · SKSlovak Medical University · SKWeill Cornell Medical College in Qatar · QA

Funding

Qatar National Research Fund NPRP 11S-1214-170101Slovak Research and Development Agency APVV-18-0088Vedecká grantová agentúra MŠVVaŠ SR a SAV (VEGA) VEGA 1/0255/20
6 · The paper itself

Abstract

Leucine is an essential, ketogenic amino acid with proteinogenic, metabolic, and signaling roles. It is readily imported from the bloodstream into the brain parenchyma. Therefore, it could serve as a putative substrate that is complementing glucose for sustaining the metabolic needs of brain tumor cells. Here, we investigated the ability of cultured human cancer cells to metabolize leucine. Indeed, cancer cells dispose of leucine from their environment and enrich their media with the metabolite 2-oxoisocaproate. The enrichment of the culture media with a high level of leucine stimulated the production of 3-hydroxybutyrate. When

Indexed as

3-methylcrotonyl-CoA carboxylaseacetyl-CoAbranched-chain amino acidcancer cellscitrateketone bodiesleucinemetabolism

Identifiers

PMID35158853
PMCPMC8833481
OpenAlexW4210630506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.